Voyager and Zevra Set for Q4 Earnings Amid Commercial and Pipeline Shifts

The upcoming fourth-quarter 2025 earnings reports for Voyager Technologies, Inc. (VYGR) and Zevra Therapeutics, Inc. (ZVRA) represent a critical juncture for two distinct strategies within the biotechnology sector. Voyager continues to champion the platform-based gene therapy model, relying on its proprietary TRACER AAV capsid discovery platform to drive high-value partnerships. In contrast, Zevra is navigating the complex transition from a clinical-stage developer to a fully integrated commercial entity focused on rare diseases. These reports, scheduled for release in early March 2026, will provide investors with essential data on partnership execution and the early commercial trajectory of newly approved therapies.

Voyager Technologies enters the earnings season with a consensus revenue estimate of $31.8 million for the fourth quarter. This figure is primarily driven by collaboration revenue and milestone payments from its deep-pocketed partners, including Neurocrine Biosciences and Novartis. The core of Voyager’s value proposition remains its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform. This technology is designed to identify AAV capsids with superior penetration of the blood-brain barrier and reduced off-target effects, particularly in the liver. As the biotech industry increasingly prioritizes de-risked assets, Voyager’s ability to generate non-dilutive capital through these partnerships is a significant differentiator. Analysts will be listening closely for updates on the company’s internal pipeline, specifically its anti-tau antibody program for Alzheimer’s disease and its SOD1-targeting gene therapy for ALS, which are expected to move toward clinical milestones in 2026.

“

Financially, both companies are expected to report net losses, with Voyager’s EPS estimated at -$0.12 and Zevra’s at -$0.23.

Zevra Therapeutics, meanwhile, is expected to report Q4 revenue of approximately $11.5 million. While smaller in scale than Voyager’s top line, Zevra’s revenue is increasingly tied to direct product sales rather than collaboration milestones. The focal point for Zevra is the commercial launch of Miplyffa (arimoclomol), which received FDA approval in late 2024 for the treatment of Niemann-Pick disease type C (NPC). NPC is a rare, progressive lysosomal storage disorder with significant unmet medical needs, and Miplyffa’s performance in its first full year of commercialization will be a bellwether for Zevra’s long-term viability. Furthermore, the company continues to market Olpruva for urea cycle disorders, a product gained through its strategic acquisition of Acer Therapeutics. Investors will be looking for specific metrics on patient enrollment, payer coverage, and the conversion rate from the company's expanded access program to commercial prescriptions.

Financially, both companies are expected to report net losses, with Voyager’s EPS estimated at -$0.12 and Zevra’s at -$0.23. These figures reflect the heavy R&D and commercialization costs inherent in the biotech business. However, the market’s focus has shifted from simple beat or miss metrics to the sustainability of the cash runway. For Voyager, the question is how long its current partnership-heavy model can fund its internal clinical ambitions without further equity dilution. For Zevra, the priority is achieving a break-even trajectory as Miplyffa gains market share. The ability of these companies to manage their burn rates while hitting clinical and commercial milestones will be the defining theme of their 2026 outlooks.